@celtliverpool.bsky.social
The Centre of Excellence for Long-acting Therapeutics (CELT) at #livuni is accelerating understanding of #longacting medicines, by combining world leading expertise in pharmacology and materials chemistry to create new interventions.
A person is holding a red AIDS awareness ribbon to the camera.
This week's long-acting news from other teams includes:
🫁 Generate:Biomedicines - phase 3 trials of a 6 month asthma treatment
💉@who.int call for rapid expansion of access to new WHO-approved tools to drive down infections on World AIDS Day
Read the full stories
www.liverpool.ac.uk/centre-of-ex...
ℹ️ Further information: liverpool.ac.uk/centre-of-ex...
LA-LINK aims to highlight evidence, gaps, and share best practice in research and development, manufacturing, delivery, and pharmacovigilance.
These workshops are part of our 'Partnership Coordination' project, funded by @unitaid.bsky.social
We'll be announcing the titles of their talks soon.
Workshop details:
⭐Application of pharmacokinetic modelling and simulation for long-acting medicines
📆Thursday 29 January 2026, 12-2.30pm (GMT)
✅Register here: www.eventbrite.co.uk/e/la-link-ja...
A picture of each speaker surround the workshop title and information
📣 SPEAKER ANNOUNCEMENT
We're excited to announce the speakers for the first of our new workshop series; LA-LINK
Professor Robert Bies - @ubuffalo.bsky.social
Dr. Harshal Hattyangdi - @liverpooluni.bsky.social
Dr. Catia Marzolini - @unil.bsky.social & @unibas.ch
Dr. @fwojara - Gulu University, Uganda
On #WorldAIDSDay, meet Dorothy from #Kenya 🇰🇪, a young mother who turned fear into hope through community support and access to paediatric #HIV treatment like #pALD. Her story shows that progress is more than medicine—it’s about solidarity and dignity.
🔗 shorturl.at/6S1Qv
#BetterMeds4Kids
Our next Community of Practice for long-acting therapeutics for maternal and paediatric health webinar
⭐Designing for the long haul: Lessons for safety studies of long-acting therapeutics from pregnancy through childhood
📆4 February 2026
🗣️Dr Adeniyi Olagunju
www.liverpool.ac.uk/centre-of-ex...
A woman looks over the land at the sunrise. Text reads "Subscribe to our mailing list"
Are you signed up to the quarterly #LONGEVITYproject newsletter?
The international consortium aim to bring long-acting preventatives/treatments to HCV, malaria and TB patients in LMICs, where these diseases have the biggest impact.
Sign up: www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
🧵2/2
💉@tballiance.bsky.social shorten TB treatment time
🌍@aidsmap.bsky.social: disparity in long-acting PrEP use in Europe
👁️EyePoint : positive phase 3 for wet AMD
Read more about the global stories from other long-acting therapeutics research teams:
www.liverpool.ac.uk/centre-of-ex...
🧵1/2
As well as @who.int's GAP-f access to better medicines for children, there is lots of news:
💉Lupin: long-acting risperidone
🧑⚕️Abbvie's LUPRON DEPOT for prostate cancer approved
🌍Gilead Sciences: start distribution of lenacapavir to Sub-Saharan Africa
www.liverpool.ac.uk/centre-of-ex...
An image from the Paediatric Health panel at the first in-person meeting of CELT's Community of Practice. The text reads "How long-acting therapeutics promise to keep children safe"
20 November is United Nations' #WorldChildrensDay.
How do we advocate for children and keep them safe?
We are actively working on child safety; to prevent malaria, and to create better pathways for children within long-acting clinical research.
Read how:
www.liverpool.ac.uk/centre-of-ex...
An illustration of a hepatitis C virus with the title "Hepatitis Testing Day 2025: Not just a US issue"
17-23 November is @worldhepalliance.bsky.social #WorldHepatitisTestingWeek.
We wrote a blog on hepatitis testing as a global issue
The #LONGEVITYproject, is working on a one-shot-cure for HCV to provide patients in LMICs treatment at diagnosis
www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
LA-LINK is part of our 'Partnership Coordination' project, funded by @unitaid.bsky.social.
The project incorporates knowledge sharing activities to accelerate equitable access to long-acting products in LMICs.
Find out more about the project via the link:
www.liverpool.ac.uk/centre-of-ex...
a chain hangs down with an image of a glowing lightbulb over a global heat map. Text reads "LA-LINK. Application of pharmacokinetic modelling and simulation for long-acting medicines. 29 January 2026, online, the first LA-LINK workshop"
📣 We're launching LA-LINK!
A new quarterly online workshop series from researchers, regulators, manufacturers, patient advocates, funders and more.
⭐Application of pharmacokinetic modelling and simulation for long-acting medicines
📆29 January
✅Registration soon
www.liverpool.ac.uk/centre-of-ex...
💡Collaboration and shared vision are key to advancing innovation and ensuring equitable patient access to transformative long-acting treatments.
Thank you to all who joined us and we look forward to continuing this important national conversation.
#HALo #LongActingTherapeutics #LifeSciences
The discussions and roundtables throughout the day explored barriers, opportunities, and the collaborative steps needed to advance the development, manufacture, and adoption of long-acting medicines across the UK.
17.11.2025 13:22 — 👍 0 🔁 0 💬 1 📌 0A huge thank you to our incredible speakers - Professor Steve Rannard (HALo), Dr Inti Qurashi (@england.nhs.uk), Susan Cole (@mhragovuk.bsky.social), Dr Christian Seiler (ViiV Healthcare) and Ian Lafferty (Upperton Pharma Solutions) - for sharing their expertise and insights.
17.11.2025 13:22 — 👍 0 🔁 0 💬 1 📌 0
An upwards shot of the Liver Building in the sunshine
Professor Steve Rannard is welcoming the delegates. The slide has the event title written on it.
During the conference as delegates sit in their chairs engaging with the presentation.
All the delegates are standing outside smiling at the camera. The River Mersey and Wirral are behind them.
🌟Securing the Future: Shaping the UK Strategy on Long-acting Therapeutics🌟
We were proud to host a collaborative event at the Liver Building, bringing together leaders from industry, academia, NHS, and regulatory bodies to shape the UK’s future long-acting therapeutics strategy.
insulin pen, diabetic measurement tools and pills on orange background
This #WorldDiabetesDay, our global long-acting therapeutics news:
💉 ADOCIA: once a month diabetes injection
🔬 SanegeneBio and Innovent: six-monthly hypertension injection
🫀 Rona Therapeutics: reduce ApoC3 and triglycerides
Read more:
www.liverpool.ac.uk/centre-of-ex...
Find out more about the Community of Practice for long-acting therapeutics in maternal and paediatric health, and how to join on the project page: www.liverpool.ac.uk/centre-of-ex...
13.11.2025 12:17 — 👍 3 🔁 2 💬 0 📌 0
A flyer with a circle of hands that reads "22/10/25. Community of Practice for long-acting therapeutics in maternal and paediatric health. Webinar: Considerations for long-acting injectable microsuspensions development - Lessons from an anti-malarial therapy."
A video of our October Community of Practice session is live.
Laxman Cherkupally from @mmv.org delivered the session titled 'Considerations for long-acting injectable microsuspension development - Lessons from an anti-malarial therapy'
Watch here: youtu.be/3PTuh4sfA4g
Calling Clinical Pharmacologists!
Are you keen to make data from published studies count beyond the paper?
PKRxiv is a managed open-access repository and visualization platform for collaborative sharing of anonymised, PK data and associated covariates.
www.liverpool.ac.uk/centre-of-ex...
Exciting meeting about new hub for long acting therapeutics today
@celtliverpool.bsky.social
@liverpooluni.bsky.social
Despite coming up to the end of 2025, we still have events, including 'Securing the future: Shaping the UK strategy on long-acting therapeutics' we're hosting for HALo tomorrow.
Find the other events we're hosting or presenting at on our Events Page: www.liverpool.ac.uk/centre-of-ex...
The LAPaL logo is the word LAPaL with 'the long-acting therapeutics patents and licences database' underneath.
Managed by @medicinespatentpool.org, LAPaL is a public database providing data on long-acting therapeutics and drug delivery technologies
This month's updates:
Long-acting semaglutide - updated global reg status and clinical trials
Lenacapavir - updated reg status
www.liverpool.ac.uk/centre-of-ex...
Dr Rajith Rajoli is working on some CELT modelling. The blog title is written over the top "Lost on your coding journey? Our pharmacology researchers can help".
29 October is @unesco.org's #WorldCodingDay.
It might not be clear how programming helps our goals to save patient lives through long-acting therapeutics, but it's actually a key part of our work.
Find out how in our blog piece:
www.liverpool.ac.uk/centre-of-ex...
An image showing the speakers for the HALo launch. They are: Professor Steve Rannard (HALo), Susan Cole (MHRA), Dr Inti Qurashi (NHS / M-RIC), Dr Christian Seiler (Viiv), Ian Lafferty (Upperton), Henry Dunne (MNS)
'Securing the future: Shaping the UK strategy on long-acting therapeutics' is the first event of the UK Hub for Advanced Long-acting Therapeutics (HALo).
📆 Thursday 6 November 2025
⏰ 10am-4pm
🌍 Liverpool, UK
Find the agenda and how to register: www.liverpool.ac.uk/centre-of-ex...
@ukri.org
A person is reading the news on their tablet
Exciting recent long-acting news from other teams includes:
@nhsengland.bsky.social roll out cabotegravir, two monthly HIV PrEP
ViiV show cabotegravir is more acceptable than lenacapavir
FDA approved @tevapharm.bsky.social UZEDY for bipolar I disorder
www.liverpool.ac.uk/centre-of-ex...
An illustration of a globe with items leading away from it, they read "materials chemistry + pharmacology + regulatory expertise + community engagement = new long-acting medicines"
Are you subscribed to our quarterly #LONGEVITYproject newsletter?
We update LONGEVITY news, opportunities and global events.
LONGEVITY, funded by @unitaid.bsky.social, is working to create long-acting malaria, TB and HCV medicines for patients in LMICs.
Sign up: www.liverpool.ac.uk/centre-of-ex...
Dr Rajith Rajoli is using modelling software on their computer. Over the image reads "Teoreler: A web-based physiologically based pharmacokinetic (PBPK) modelling application for the simulation and extrapolation of drug use scenarios. This application simulates drug pharmacokinetics of small molecules using complex mathematical equations to predict the efficacy of drugs in the human body in a variety of species and populations."
Have you used Teoreler for any research that has since been published?
If so, we'd like to add you to the list of publications Teoreler was used for: www.liverpool.ac.uk/centre-of-ex...
Email us on askcelt@liverpool.ac.uk
Our webinar is tomorrow (22 October) at 12pm (BST/GMT+1).
Guest speaker Laxman Cherkupally, from @mmv.org, will present 'Considerations for long-acting injectable microsuspension development - Lessons from an anti-malarial therapy. V2'.
Find out how to register: www.liverpool.ac.uk/centre-of-ex...
